These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18329046)

  • 1. Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients.
    Ferrari M; Termine C; Franciotta D; Castiglioni E; Pagani A; Lanzi G; Marino F; Lecchini S; Cosentino M; Balottin U
    J Psychiatr Res; 2008 Nov; 43(1):24-9. PubMed ID: 18329046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tourette syndrome. Genetics, neuroanatomy and neurotransmitters].
    Debes NM; Skov L; Hjalgrim H
    Ugeskr Laeger; 2008 Aug; 170(35):2695-700. PubMed ID: 18761860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome.
    Ghanizadeh A; Mosallaei S
    Brain Dev; 2009 Jan; 31(1):15-9. PubMed ID: 18558469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obsessive compulsive behaviour and depressive symptoms in young people with Tourette syndrome. A controlled study.
    Robertson MM; Banerjee S; Eapen V; Fox-Hiley P
    Eur Child Adolesc Psychiatry; 2002 Dec; 11(6):261-5. PubMed ID: 12541004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal adenosine and dopamine receptor expression in lymphocytes of Lesch-Nyhan patients.
    García MG; Puig JG; Torres RJ
    Brain Behav Immun; 2009 Nov; 23(8):1125-31. PubMed ID: 19635551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of intronic variants of the BTBD9 gene with Tourette syndrome.
    Rivière JB; Xiong L; Levchenko A; St-Onge J; Gaspar C; Dion Y; Lespérance P; Tellier G; Richer F; Chouinard S; Rouleau GA;
    Arch Neurol; 2009 Oct; 66(10):1267-72. PubMed ID: 19822783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal expression of dopamine and serotonin transporters associated with the pathophysiologic mechanism of Tourette syndrome.
    Jijun L; Zaiwang L; Anyuan L; Shuzhen W; Fanghua Q; Lin Z; Hong L
    Neurol India; 2010; 58(4):523-9. PubMed ID: 20739786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Habit learning in Tourette syndrome: a translational neuroscience approach to a developmental psychopathology.
    Marsh R; Alexander GM; Packard MG; Zhu H; Wingard JC; Quackenbush G; Peterson BS
    Arch Gen Psychiatry; 2004 Dec; 61(12):1259-68. PubMed ID: 15583117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catecholamine-related gene expression in blood correlates with tic severity in tourette syndrome.
    Gunther J; Tian Y; Stamova B; Lit L; Corbett B; Ander B; Zhan X; Jickling G; Bos-Veneman N; Liu D; Hoekstra P; Sharp F
    Psychiatry Res; 2012 Dec; 200(2-3):593-601. PubMed ID: 22648010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage study of the dopamine D5 receptor gene and Gilles de la Tourette syndrome.
    Barr CL; Wigg KG; Zovko E; Sandor P; Tsui LC
    Am J Med Genet; 1997 Feb; 74(1):58-61. PubMed ID: 9034008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.
    Steeves TD; Fox SH
    Prog Brain Res; 2008; 172():495-513. PubMed ID: 18772048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the presence of comorbidities in a Danish clinical cohort of children with Tourette syndrome.
    Mol Debes NM; Hjalgrim H; Skov L
    J Child Neurol; 2008 Sep; 23(9):1017-27. PubMed ID: 18827268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding disability in Tourette syndrome.
    Pringsheim T; Lang A; Kurlan R; Pearce M; Sandor P
    Dev Med Child Neurol; 2009 Jun; 51(6):468-72. PubMed ID: 19018838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis.
    Yoon DY; Gause CD; Leckman JF; Singer HS
    J Neurol Sci; 2007 Apr; 255(1-2):50-6. PubMed ID: 17337006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Rorschach test and Gilles de la Tourette's syndrome: a pilot case-control study.
    Balottin U; Rossi M; Rossi G; Viganò L; Nanti M; Salini S; Lanzi G; Termine C
    Brain Dev; 2009 Oct; 31(9):657-65. PubMed ID: 19041203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant Tourette syndrome.
    Cheung MY; Shahed J; Jankovic J
    Mov Disord; 2007 Sep; 22(12):1743-50. PubMed ID: 17566119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of quality of life in children with Gilles de la Tourette syndrome.
    Bernard BA; Stebbins GT; Siegel S; Schultz TM; Hays C; Morrissey MJ; Leurgans S; Goetz CG
    Mov Disord; 2009 May; 24(7):1070-3. PubMed ID: 19306279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction.
    Goodarzi A; Vousooghi N; Sedaghati M; Mokri A; Zarrindast MR
    Eur J Pharmacol; 2009 Aug; 615(1-3):218-22. PubMed ID: 19445922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspects of Tourette syndrome].
    Debes NM; Hjalgrim H; Skov L
    Ugeskr Laeger; 2008 Aug; 170(35):2701-3. PubMed ID: 18761861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls.
    Singer HS; Hong JJ; Yoon DY; Williams PN
    Neurology; 2005 Dec; 65(11):1701-7. PubMed ID: 16207842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.